# **Guided Tour of K Awards**

Sergei Radaev, Ph.D.
Program Director
Center for Cancer Training
240-276-5630

# Disclosure Information Sergei Radaev, PhD

**No Relevant Disclosures** 

# **Topics to cover**

- What is the Timing and Schedule?
- Who are the Members of the Review Panel?
- How are Grants Discussed/Decisions Made?
- How Does the Scoring Process Work/Each Section Scored?
- Understanding and Making the Best Use of Feedback Received from Review Panels?
- How to Plot the Best Course of Action Whether a Grant Application Is or Is Not Funded?

What is the Timing and Schedule?

#### **NIH Peer Review Process**

Division of Receipt and Referral (CSR) Initial Peer Review (IC or CSR) Second Level of Review (Council) **Funding decisions (IC director) Award** 



## **Standard Due Dates for K-application Submission**


https://grants.nih.gov/grants/how-to-apply-application-guide/due-dates-and-submission-policies/standard-due-dates.htm

Mechanisms	Cycle I Due Date	Cycle II Due Date	Cycle III Due Date
<u>New</u> K grant applications	February 12	June 12	October 12
<u>Resubmission</u> K grant applications	March 12	July 12	November 12
Scientific Merit Review (IRG)	June - July	October - November	February - March
Advisory Council Review	September - October	January - February	May - June
Earliest Project Start Date	December*	April	July

<sup>\* -</sup> Awarding components may not always be able to honor the requested start date of an application



## Points of contact during the lifecycle of a grant






#### Contacting Program Official before application submission

- Help in clarifying eligibility questions/issues
- Confirm whether your project is a good fit for the NIH IC, e.g., NCI
- General advise on how to prepare your application
- Discuss important points to consider

#### **NIH Peer Review Process**





### **Assignment Request Form and Cover Letter**


- You can request an NIH IC or a specific study section.
- Identify scientific areas of expertise needed to review your application
- List individuals who should not review your application and why (e.g., potential conflict)

Even if you don't request a specific NIH IC or study section, DRR will assign your application to the appropriate IC/study section

OMB Number: 0925-0001 Expiration Date: 10/31/2018

	Funding Opportunity Number:					
	Funding Opportunity Title:					
	Awarding Component Assignment Req	uest (optional)				
	If you have a preference for an Awarding ( abbreviation (e.g., NCI for National Cancer considered; however, locus of review is pre-	Institute) in "Assign to/Do N	ot Assign To Awarding C	omponent" sections below. Y	our first choice should be in co	
	Information about Awarding Components of	can be found here: https://gra	ants.nih.gov/grants/phs_a	ssignment_information.htm#/	AwardingComponents	
Request NIH IC	Assign to Awarding Component:	1	2	3		
(e.g., NCI)	Do Not Assign to Awarding Component:					
	Study Section Assignment Request (op	tional)				
	If you have a preference for a study sectio "Assign to/Do not Assign to Study Section" applications and assignment requests can	sections below. Your first ch				
	For example, you would enter "CAMP" if you to the Healthcare Delivery and Methodolog					
	Information about Study Sections can be f	ound here: https://grants.nih.	gov/grants/phs_assignm	ent_information.htm#StudySe	ection	
Request Study section		1	2	3		
(e.g., NCI-I)	Assign to Study Section: Only 20 characters allowed					
(e.g.,,	Do Not Assign to Study Section: Only 20 characters allowed					
	List Individuals who should not review	your application and why (o	ptional)			Only 1000 characters allowed
Identify conflicts						
Suggest expertise required						
to review your application	Identify Scientific areas of expertise new Note: Please do not provide names of indi		tion (optional)			
		1	2	3	4	5
NATIONAL CANCER INSTITUTE	Expertise: Only 40 characters allowed					

## **Find a Study Section**



## Scientific Review Officer (SRO) manages Initial Peer Review

- Assembles panel of reviewers with appropriate expertise
- Manages Conflicts of Interest
- Assigns applications to reviewers
- Manages initial peer review meeting
- Prepares and releases summary statements

Who are the Members of the Review Panel?

## How reviewers are selected?

- Recognized authorities in their field and active scientists
- Standing committee maintains diversity with respect to the geographic distribution, gender, race and ethnicity of the membership
- Reviewers must be dedicated to high quality, fair reviews.
- Each scientific area reviewed by the study section needs appropriate expert representation
- Study sections that review multidisciplinary or interdisciplinary applications have a greater need for scientists who have broader expertise or who have demonstrated the capacity to appreciate and evaluate areas of science outside their immediate area of expertise

## NCI study sections that review <u>cancer-focused</u> K-grants

NCI-I - Transition to Independence

NCI-J - Career Development






If there is a conflict with the review panel the application will be reviewed by a Special Emphasis Panel (SEP)

NCI-I: 22 regular members + *ad hocs* reviews ~100+ applications


NCI-J: 18 regular members + ad hocs reviews ~70+ applications

## **Find a Study Section**





# http://www.cancer.gov/grants-training/training/funding

# NIH NATIONAL CANCER INSTITUTE



# NIH NATIONAL CANCER INSTITUTE







#### STUDY SECTION ROSTER INFORMATION

To view other meetings from NCI I choose calendar year: 2017 ▼ Go

Study Section	Membership Roster	Committee Name	SKU (E-MAIL)	Meeting Rosters
NCI I	<u>VIEW</u>	SUBCOMMITTEE I - TRANSITION TO INDEPENDENCE	TANG, DELIA	10/18/17 06/14/17 02/16/17

Last Update: 10/27/17

IC's Rosters Index OER: Peer Review and Policy Issues



#### Subcommittee I - Transition to Independence

(Terms end 6/30 of the designated year)
ROSTER

#### CHAIRPERSON

#### \_\_\_\_ End of term

BOUTON, AMY H, PHD (18)

PROFESSOR AND ASSOCIATE DEAN FOR GRADUATE AND MEDICAL SCIENTIST PROGRAMS
DEPARTMENT OF MICROBIOLOGY, IMMUNOLOGY AND
CANCER BIOLOGY
UNIVERSITY OF VIRGINIA SCHOOL OF MEDICINE

AKPORIAYE, EMMANUEL T., PHD (19)
ADJUNCT FULL MEMBER
EARLE A. CHILES RESEARCH INSTITUTE
PROVIDENCE PORTLAND CANCER CENTER
FOUNDER, VEANA THERAPEUTICS
PORTLAND. OR. 97213

CHARLOTTESVILLE, VA. 22908

ARBAB, ALI SYED, MD, PHD (19)
PROFESSOR; LEADER OF TUMOR ANGIOGENESIS INITIATIVE; DIRECTOR OF CORE IMAGING FACILITY FOR SMALL ANIMALS
DEPARTMENT OF BIOCHEMISTRY AND MOLECULAR BIOLOGY
COLLEGE OF GRADUATE STUDIES
AUGUSTA UNIVERSITY
AUGUSTA. GA, 30912

BLACK, JENNIFER D., PHD (18)
PROFESSOR; CO-LEADER, GASTROINTESTINAL CANCER PROGRAM
EPPLEY INSTITUTE FOR RESEARCH IN CANCER
AND ALLIED DISEASES
UNIVERSITY OF NEBRASKA MEDICAL CENTER
OMAHA, NE, 68198

CHAN, REBECCA J., MD, PHD (19)
ASSOCIATE PROFESSOR OF PEDIATRICS
DEPARTMENT OF PEDIATRICS AND OF MEDICAL
AND MOLECULAR GENETICS
INDIANA UNIVERSITY SCHOOL OF MEDICINE
INDIANAPOLIS. IN. 46202

CLARKE, JENNIFER L., PHD (19)
PROFESSOR
DEPARTMENT OF STATISTICS
DEPARTMENT OF FOOD SCIENCE AND TECHNOLOGY
DIRECTOR, QUANTITATIVE LIFE SCIENCES INITIATIVE
UNIVERSITY OF NEBRASKA - LINCOLN
LINCOLN. NE. 68586207





#### STUDY SECTION ROSTER INFORMATION

To view other meetings from NCI I choose calendar year: 2017 ▼ Go

Study Section	Membership Roster	D Roster Committee Name SRO (E-MAIL)		Meeting Rosters
NCI I	VIEW	SUBCOMMITTEE I - TRANSITION TO INDEPENDENCE	TANG. DELIA_	10/18/17 06/14/17 02/16/17

Last Update: 10/27/17

IC's Rosters Index OER: Peer Review and Policy Issues Webmaster



#### SUBCOMMITTEE I - TRANSITION TO INDEPENDENCE

NCII 10/18/17 - 10/19/17 Meeting Roster

Notice of NIH Policy to All Applicants: Meeting rosters are provided for information purposes only. Applicant investigators and institutional officials must not communicate directly with study section members about an application before or after the review. Failure to observe this policy will create a serious breach of integrity in the peer review process, and may lead to actions outlined in NOT-OD-14-073 and NOT-OD-15-106, including removal of the application from immediate review.

#### CHAIRPERSON

BOUTON, AMY H, PHD
PROFESSOR AND ASSOCIATE DEAN FOR GRADUATE AND MEDICAL SCIENTIST PROGRAMS
DEPARTMENT OF MICROBIOLOGY, IMMUNOLOGY AND
CANCER BIOLOGY
UNIVERSITY OF VIRGINIA SCHOOL OF MEDICINE
CHARLOTTESVILLE, VA. 22908

#### MEMBERS

ARBAB, ALI SYED, MD, PHD
PROFESSOR; LEADER OF TUMOR ANGIOGENESIS INITIATIVE; DIRECTOR OF CORE IMAGING FACILITY FOR SMALL ANIMALS
DEPARTMENT OF BIOCHEMISTRY AND MOLECULAR BIOLOGY
COLLEGE OF GRADUATE STUDIES
AUGUSTA UNIVERSITY
AUGUSTA, GA, 30912

Adhoc reviewer

BAKKENIST, CHRISTOPHER J., PHD \*
ASSOCIATE PROFESSOR AND VICE CHAIR
DEPARTMENT OF RADIATION ONCOLOGY
HILLMAN CANCER CENTER
UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE
PITTSBURGH PA. 15213

BLACK, JENNIFER D., PHD
PROFESSOR; CO-LEADER, GASTROINTESTINAL CANCER PROGRAM
EPPLEY INSTITUTE FOR RESEARCH IN CANCER
AND ALLIED DISEASES
UNIVERSITY OF NEBRASKA MEDICAL CENTER

Up to 40+% of NCI-I panel can be *ad hocs* !!!



**How are Grants Discussed/Decisions Taken?** 

How Does the Scoring Process Work/Each Section Scored?

#### **Details of the Initial Peer Review Process**

SRO assigns 3 reviewers/grant You can submit 4-6 weeks before review meeting your "postsubmission" materials to the SRO no later than Reviewers submit their critiques 30 days before and scores the review a few days before review meeting meeting **Decision Not** to Discuss an Discussion of ~top 50% of the applications (preliminary scores) application at the review meeting must be unanimous Scores are released ~1-2 days after the review meeting All applications **Summary statements released** receive ~ 4-8 weeks (NCI) after the summary review meeting statements NATIONAL CANCER INSTITUTE

#### **Initial Peer Review Meeting**



NCI-I: 22 regular members + *ad hoc* reviewers; reviews ~100+ applications

NCI-J: 18 regular members + *ad hoc* reviewers; reviews ~70+ applications

#### **Review Process for Scored/Discussed Applications**

**Assigned Reviewers State their Preliminary Overall Impact Scores** 

Assigned Reviewers Describe/Summarize an Application Focusing on Strengths and Weaknesses including, HS, VA and Biohazards

**Entire Review Panel Discusses the Application** 

Assigned Reviewers State their Final Overall Impact Scores – Scoring Range is Determined

**Reviewers Record their Scores** 

Budget, RCR Training, Resource Sharing Plan, Authentication of Key Biological/Chemical Resources Discussed

Some
Reviewers
might
Score
Outside
the Range

### **Scoring/Summary Statements**

This scoring system is used for both overall impact score and criterion scores

Overall Impact or Criterion Strength	Score	Descriptor
	1	Exceptional
High	2	Outstanding
	3	Excellent
	4	Very Good
Medium	5	Good
	6	Satisfactory
	7	Fair
Low	8	Marginal
	9	Poor



#### SUMMARY STATEMENT

(Privileged Communication)

Release Date: 07/05/2017

Revised Date:

240-276-5630 sradaev@mail.nih.gov

SERGEI RADAEV

PROGRAM CONTACT:

Application Number: 1 K99 CA012345-01

Principal Investigator

GOOD, FELLOW

Applicant Organization: HARVARD MEDICAL SCHOOL

Review Group: NCI-I

Subcommittee I - Transition to Independence

Meeting Date: 06/14/2017 RFA/PA: PA16-193 PCC: AHTR

Council: OCT 2017

Requested Start: 10/01/2017

> Project Title: Analysis of something important

SRG Action: Impact Score:15

Visit https://grants.nih.gov/grants/next\_steps.htm Next Steps:

**Human Subjects:** 10-No human subjects involved

30-Vertebrate animals involved - no SRG concerns noted Animal Subjects:







#### **Scoring/Summary Statements**

(Once summary statement is released Program Official once again becomes your point of contact )

SRG Action: Impact Score:35

Next Steps: Visit http://grames.nih.gov/grants/next\_steps.htm

Human Subjects: 30-Human sinvolved - Certified, no SRG concerns Animal Subjects: 30-Vertebrate mals involved - no SRG concerns noted

Gender: 1A-Both gend scientifically acceptable

Minority: 1A-Minorities non-minorities, scientifically acceptable and Adults, scientifically acceptable

Clinical Rese - not NIH-defined Phase III Trial

SRG Action: ++
Next Steps: Viet http://grants

Next Steps: Viet http://grants.nih.gov/grants/next\_steps.htm Human Subjects: http://grants.nih.gov/grants/next\_steps.htm

Animal Subjects: 3 ertebrate animals involved - no SRG concerns noted

An average of individual <u>overall</u>
impact scores of all panel members
present during the discussion
multiplied by 10

Not Discussed

#### **Scoring/Summary Statements**

#### **CRITIQUE 1**

Candidate:

Career Development Plan/Career Goals /Plan to Provide Mentoring:

Research Plan:

Mentor(s), Co-Mentor(s), Consultant(s), Collaborator(s):

Environment Commitment to the Candidate:



The overall impact score of an assigned reviewer is based on the criterion scores + additional review criteria: HS, VA, and Biohazards

An overall impact score for this reviewer could be anywhere between 1 and 4

Keep in mind that some reviewers forget to update their scores and critiques after the discussion

# Understanding and Making the Best Use of Feedback Received from Review Panels?

How to Plot the Best Course of Action Whether a Grant Application Is or Is Not Funded?

Just a reminder: **SRO** prepares and releases your summary statements

Check your eRA Commons account !!!


After carefully reading and discussing your summary statements with your mentor(s), you can contact your Program Official

#### **Discussing Summary Statements with Program Official**

- The likelihood of NIH funding of the application: based on the impact score/percentile, funding situation, other factors
- Further discussion of the reviewers' comments
- Whether to submit a new application or resubmit an application
- What to address in your next submission
- Acceptable bases for appealing the peer review process


## **NCI K99/R00 Success Rates**

https://report.nih.gov/success\_rates/



## K99/R00 success rates by NIH IC (2016)

https://report.nih.gov/success\_rates/



# **NCI Program Contacts (K99/R00)**

Sergei Radaev, PhD

E-mail: <a href="mailto:sradaev@mail.nih.gov">sradaev@mail.nih.gov</a>

Michael Schmidt, PhD

E-mail: <u>mschmidt@mail.nih.gov</u>

When you contact us for the first time, it is usually a good idea to include your biosketch and a draft of your specific aims into your email



www.cancer.gov/espanol